# Gilead Sciences, Inc. – Consensus ‘buy’ rating and 1.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.consensus-buy-rating-and-1.1-upside-potential/4121175119
- Published: 2024-10-23T15:19:26+01:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** with ticker code (GILD) have now 28 analysts in total 
covering the stock. The consensus rating is pointing to ‘buy’. The target price 
High/Low ranges between $123.00 and $69.00 and has a mean target at $87.22. Now 
with the previous closing price of $86.29 this is indicating there is a potential
upside of 1.1%. It’s also worth noting that there is a 50 day moving average of 
$81.51 and the 200 moving average now moves to $74.06. The company has a market 
cap of 109.76B. The price for the stock stands currently at: $88.16 USD

 The potential market cap would be $110,941,248,916 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 107.51, revenue per share of $22.30
and a 11.55% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: